Anti-MTX5:Cytolysin Antibody Drug Conjugate

The in vivo antitumoral efficacy of Oncomatryx Anti-MTX5:Cytolysin ADC, OMTX705, was tested at two different laboratories, in several different pancreatic cancer patient-derived subcutaneous xenograft murine models.

OMTX705 led to 100% tumor growth inhibition as single agent and even tumor regression when combined with Gemcitabine and/or Abraxane.



No mice weight loss occurred when administering OMTX705-558, as single agent or in combination with Gemcitabine and/or abraxane.




By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.